Merck KGaA
MRK.DEAction· XETRA· EUR
L'essentiel à retenir
- • Dernier cours : 143,15 € (cours différé)
- • Variation sur 1 an : +29,78 %
- • Type d'actif : Action
- • Place de cotation : XETRA
- • Devise de cotation : EUR
- • Clôture précédente : 142,85 €
Informations
- Symbole
- MRK.DE
- Type
- Action
- Place
- XETRA
- Devise
- EUR
- Clôture veille
- 142,85 €
- Variation 1 an
- +29,78 %
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
BAAR, Switzerland, July 29, 2026--Evinova, a global leader in AI-native clinical development technology, today announced a new multi-year strategic collaboration to accelerate global clinical development with Merck KGaA, Darmstadt, Germany, a leading science and technology company. Merck KGaA, Darmstadt, Germany will adopt the end-to-end capabilities of the Evinova AI-Native platform covering all modules of study design, document authoring, and downstream automation to significantly reduce time,
Yahoo Finance · 29/07/2026 · lire l'article ↗
Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade
Merck KGaA (MKKGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Yahoo Finance · 23/07/2026 · lire l'article ↗
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Yahoo Finance · 23/07/2026 · lire l'article ↗
Merck KGaA (XTRA:MRK) Opens New Darmstadt Testing Site As Pipeline Progress Builds
Merck KGaA’s MilliporeSigma unit has opened a new BioReliance testing facility in Darmstadt, Germany, expanding its biopharmaceutical testing footprint in Europe. The company reported a European label update for Erbitux in colorectal cancer, reflecting regulatory progress for its oncology portfolio. Enpatoran, Merck KGaA’s investigational lupus therapy, has received US FDA Breakthrough Therapy designation. Merck KGaA (XTRA:MRK) is adding fresh momentum to its healthcare and life science...
Yahoo Finance · 18/07/2026 · lire l'article ↗
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor
Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contributions to more than 30 oncology programsSEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer. The Company also announc
Yahoo Finance · 08/07/2026 · lire l'article ↗
Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline
Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.
Yahoo Finance · 07/07/2026 · lire l'article ↗
Titres et résumés fournis par les sources d'origine (flux Yahoo Finance). Cliquez pour lire l'article complet.
Questions fréquentes sur Merck KGaA
- Quel est le cours actuel de Merck KGaA ?
- Le dernier cours connu de Merck KGaA (MRK.DE) est de 143,15 € (cours différé, fourni à titre informatif). Cette page est mise à jour régulièrement.
- Quelle est la performance de Merck KGaA sur un an ?
- Sur les 12 derniers mois, Merck KGaA (MRK.DE) affiche une variation de +29,78 %. Les performances passées ne préjugent pas des performances futures.
- Comment suivre Merck KGaA dans mon portefeuille ?
- Créez un compte gratuit sur AssetApp, ajoutez MRK.DE à l'un de vos portefeuilles et suivez sa valeur, vos plus-values et son actualité — aux côtés de vos autres actifs.
Actifs similaires
Merck KGaA : suivre cet actif
Merck KGaA (MRK.DE) est une action coté sur XETRA en EUR. Avec AssetApp, ajoutez MRK.DE à votre portefeuille pour suivre sa valeur, vos gains latents et réalisés, et l'évolution de votre patrimoine — sans dépendre de votre courtier.
Suivre MRK.DE gratuitement